Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant Hearings Offer Starting Point For Vioxx Investigation

Executive Summary

The congressional interest in pediatric antidepressant safety data will provide a springboard for investigations into the withdrawal of Merck's COX-2 inhibitor Vioxx

You may also be interested in...



Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers

Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers

Vioxx, Drug Safety Issues Top Health Committee Agenda – If Gregg Stays

The Senate Health Committee plans to look into FDA's handling of Vioxx, antidepressant safety and flu vaccine, committee counsel Steve Irizarry said at the Healthcare Distribution Management Association annual meeting in Palm Desert, Calif. Nov. 4

Related Content

UsernamePublicRestriction

Register

PS044781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel